Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high32.00 20/07/17
52 week low17.25 26/09/16
52 week change 12.00 (63.16%)
4 week volume3,359,292 26/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to ...

Allergy Therapeutics ahead of forecasts

Allergy Therapeutics expects revenues for the year ended 30 June to be ahead of market forecasts at 64.1m (2016: 48.5m). A ...

Trading Update

RNS Number: 3133L Allergy Therapeutics PLC 18 July 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update 15% constant currency revenue growth Double-digit compound annual revenue growth over the past 18 years 18 July 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in...

Publication of adjuvant studies in journals

RNS Number: 2501K Allergy Therapeutics PLC 06 July 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Two studies of adjuvants in malaria and influenza vaccines published in peer-reviewed journals ~ Publications demonstrate the potential of Allergy Therapeutics' novel adjuvant systems in infectious diseases , further bro...

Investor and analyst site visits

RNS Number: 2147J Allergy Therapeutics PLC 27 June 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Investor and analyst site visits 27 June 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, is hosting a site visit at its corporate headquarters for sell-side analysts today ...

Allergy Therapeutics hosts satellite symposium at EAACI

Allergy Therapeutics hosted a satellite symposium at the 36th annual congress of the European Academy of Allergy and C...

Satellite Symposium at EAACI 2017

RNS Number: 3866I Allergy Therapeutics PLC 19 June 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics hosts satellite symposium at EAACI 2017 ~ World-leading experts discuss allergy immunotherapies ~ Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialisi...

Directorate changes

RNS Number: 2053H Allergy Therapeutics PLC 06 June 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Directorate changes 6 June 2017 Allergy Therapeutics (AIM:AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces the appointment of Dr Tunde Otulana to its Board of ...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
19/07/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only on a ‘Named...
hardman & co
Allergy Therapeutics plc
06/04/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’...
Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...

Latest discussion posts More

  • Re: As good as it gets at this stage.

    it appears that finnCap have today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 46p (from 43p).This follows AGY ...
    18-Jul-2017
    d gaser
  • As good as it gets at this stage.

    Well done and thanks to all at AGY. You will not see many updates better than that one!
    18-Jul-2017
    Baffler
  • Dates for your diary:

    Dates for your diary: 18 07 2017 Trading update 28 09 2017 Preliminary Annual Results 2017 Announcement (tentative) 22 11 2017 AGM (tentative)
    17-Jul-2017
    jres

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.26%
BP22%
SIRIUS MINERALS19%
NATIONAL GRID18%
BARCLAYS16%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY